MIRA INFORM REPORT

 

 

 

Report Date :

22.07.2008

 

IDENTIFICATION DETAILS

 

Name :

AMROS PHARMACEUTICALS

 

 

Registered Office :

A-96, S.I.T.E., North Karachi, Karachi

 

 

Country :

Pakistan

 

 

Date of Incorporation :

2001

 

 

Com. Reg. No.:

1055570

 

 

Legal Form :

Proprietorship

 

 

Line of Business :

Manufacture and Marketing of Pharmaceutical Products

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Small Concern

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

 

 

 

                                   

Business Name

 

AMROS PHARMACEUTICALS

 

 

Full Address       

 

Registered Address

A-96, S.I.T.E., North Karachi, Karachi, Pakistan

                       

Tel

92 (21) 6351921, 6351807

Fax

92 (21) 6351807

 

 

 

 

 

Short Description Of Business

 

Nature of Business           

Manufacture & Marketing of Pharmaceutical Products

Year Established

2001

National Tax #

1055570

 

 

Branches

           

434 - 435, 4th Floor, Hoor Centre,

North Napier Road. Karachi,

Pakistan

 

 

Legal Status

 

Subject Company was established as a Proprietorship business in 2001

 

 

Details of Management

 

Names

Nationality

Address

Occupation

Designation

Mr. Abdul Razzaque

 

 

 

Pakistani

 

 

 

 

434 - 435, 4th Floor, Hoor Centre, North Napier Road. Karachi

Business

 

 

 

 

Proprietor

 

 

 

 

 

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

                        None                                             

           

B.         Associated Companies

 

            - Do -   

 

 

Products

 

(1) Subject Company is engaged in manufacture & marketing of Pharmaceutical Products.

 

(2)   It purchases raw material against D/A, D/P basis.

 

(3) Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located in Hyderabad, Karachi & Interior Sindh.

 

(4) Subject operates from caption leased factory premises of area measuring   3,000 Sq.Yard. which is situated in industrial area.

 

(5)  Subject employs about 55 persons in its set up.

 

 

Products

           

ALIUM, AMDIC, AMDIK, AMFIC, AMLIN, AMMONIUM CHLORIDE, AMOGEL, AMOXAZOL, AMROBION, AMROFEN, AMROLKA, AMRON, AMROPYRON, AMROTON, ASPIRIN, BUFAC, CHLORAMPHENICOL, DEXAMETHASONE, DIAZEPAM, DICLOFENAC, DIPYRON, FACTUM, FURAZOLIDONE, GENTAMYCIN, HYOSCINE, LINCOMYCIN, NEKACYN, NEODEX, NEOMYCIN, OXYTETRACYCLINE, OXYTOCIN, PARACETAMOL, PHENIRAMINE, PHENOBARBITONE, PHENYLBUTAZONE, SOPRAN, STEBID, TOCIN, VITAMIN B12, VITAMIN-C.

 

 

Trade Suppliers

 

(1) VITAL-CHEM ZHUHAI CO. LTD, CHINA.

(2) SINOCHEM SHANGHAI CORPORATION, CHINA.

 

 

Annual Sales Volume

 

Year
In Pak Rupees

2006

25,000,000/- (Estimated)

 

 

 

Capacity & Production

           

The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.

 

 

Bankers

 

Bank Alhabib Limited, Pakistan.

Standard Chartered Bank, Pakistan.

Faysal Bank Limited, Pakistan.

 

 

Memberships

 

·         Karachi Chamber of Commerce & Industry.(KCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

             Rs. 71.50

UK Pound

1

             Rs. 142.20

Euro

1

             Rs. 112.90

 

 

Comments

 

Subject Company was established in 2001 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. Company can be considered for normal business dealings at usual trade terms and conditions.

 

 

 

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.42.33

UK Pound

1

Rs.84.32

Euro

1

Rs.66.75

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions